The Journal of Neuroimmune Pharmacology (JNIP) is the peer-reviewed journal of the Society on NeuroImmune Pharmacology. JNIP interfaces the disciplines of immunology, pharmacology and experimental neuroscience by acting as a platform for research discoveries into the pathogenesis and pharmacology of nervous system disorders affecting the immune system and vice versa. Original interdisciplinary scientific contributions, concise "opinion," and broad reviews are welcome. Research areas reporting in JNIP include receptor cell signaling, the pathobiology, cognitive neuroscience, psychopharmacology and immunity of drugs of abuse, neurodegenerative disorders, neurovirology, neuroimmunology, and neuropharmacology. Manuscripts must include original research linked to the immunology and pharmacology of human neurologic and neuropsychiatric disorders including substance abuse, depression, psychosis, Alzheimer's and Parkinson's disease, Amyotrophic Lateral Sclerosis, Multiple Sclerosis, HIV-associated neurocognitive disorders, neuroendocrine and microbial infections, and immunological, toxic and metabolic disorders of the brain, spinal cord, and peripheral nerves. Topical studies of brain-immune interactions include, but are not limited to: (1) leukocyte trafficking into the nervous system; (2) innate immunity in the nervous system; (3) pathophysiology of neurodegenerative diseases; (4) effects of endogenous ligands on brain-immune interactions (neuronal-peripheral immune; neuronal-glial); (5) effects of drugs of abuse and other pharmacophores on peripheral immune responses, (6) medicinal chemistry and drug development; (7) vaccine approaches for neurologic and neuropsychiatric diseases; (8) bioimaging and proteomics; (9) nanomedicine; and (10) immune surveillance for microbial infections. JNIP will identify novel pharmacologic discoveries (organized action of drug targets, mechanisms, and development) of brain-immune interactions with a potential towards modifying the cellular and systemic responses that affect disease or lead to amelioration of brain injury and immune dysfunction.

Journal information

  • Howard Gendelman
Publishing model
Hybrid. Open Access options available

Journal metrics

3.87 (2018)
Impact factor
3.988 (2018)
Five year impact factor
24 days
Submission to first decision
111 days
Submission to acceptance
100,656 (2018)

Latest articles

Societies, partners and affiliations


Note this is only the net price. Taxes will be calculated during checkout.
  • Immediate online access
  • Full Journal access includes all articles
  • Downloadable in PDF
  • Subscription expires 12/31/2020


About this journal

Electronic ISSN
Print ISSN
Abstracted and indexed in
  3. Biological Abstracts
  4. EBSCO Biomedical Reference Collection
  5. EBSCO Discovery Service
  7. Gale
  8. Gale Academic OneFile
  9. Gale InfoTrac
  10. Google Scholar
  11. Institute of Scientific and Technical Information of China
  12. Japanese Science and Technology Agency (JST)
  13. Journal Citation Reports/Science Edition
  14. Medline
  15. Meta
  16. Naver
  17. OCLC WorldCat Discovery Service
  18. Pathway Studio
  19. ProQuest Central
  20. ProQuest Health & Medical Collection
  21. ProQuest Health Research Premium Collection
  22. ProQuest Medical Database
  23. ProQuest-ExLibris Primo
  24. ProQuest-ExLibris Summon
  25. Reaxys
  26. SCImago
  27. SCOPUS
  28. Science Citation Index Expanded (SciSearch)
Copyright information

Rights and permissions

Springer Nature policies

© Springer Science+Business Media, LLC, part of Springer Nature